Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936373 | 0.87 | PLA2G10 (0.46) | HCAR2SMN1; SMN2PTPN1PTPN2PTPN6 | |
| SCHEMBL27724759 | 0.87 | LMNA (0.46) | HCAR2RNASEH1SMN1; SMN2TSHRBCL2 | |
| SCHEMBL7421844 | 0.83 | TDP1 (0.50) | SMN1; SMN2TSHRKDM4ELMNAKMT2A | |
| SCHEMBL948640 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2TSHRKDM4ELMNAMEN1 | |
| SCHEMBL30094007 | 0.78 | CNR2 (0.46) | SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL4857853 | 0.77 | BCL2 (0.48) | HCAR2SMN1; SMN2BCL2BCL2L1MEN1 | |
| SCHEMBL591059 | 0.76 | HCAR2 (0.44) | HCAR2KDM4E | |
| SCHEMBL3044296 | 0.76 | HCAR2 (0.37) | HCAR2SMN1; SMN2KDM4ELMNA | |
| SCHEMBL9956509 | 0.74 | HCAR2 (0.33) | HCAR2KDM4ELMNA | |
| SCHEMBL1018503 | 0.74 | KDM4E (0.46) | HCAR2TSHRKDM4ELMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008027442-A2 | ABUSE DETERRENT ORAL PHARMACEUTICAL FORMULATIONS OF OPIOID AGONISTS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-03-06 | — | — | WO | claimed |
| WO-2008024408-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS FOR APPLICATION TO THE SKIN AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2008021394-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-02-21 | — | — | WO | claimed |
| US-20240174649-A1 | CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-05-30 | — | — | US | disclosed |
| WO-2022165432-A1 | CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-3317269-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-05-09 | — | — | EP | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| EP-2451450-B1 | Inhibitors of proline racemase enzymes for the treatment of Trypanosoma spp infections | PASTEUR INSTITUT (FR) | 2014-07-02 | — | — | EP | disclosed |
| EP-2451450-A1 | NEW INHIBITORS OF PROLINE RACEMASE ENZYMES | Institut Pasteur (FR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004323-A1 | NEW INHIBITORS OF PROLINE RACEMASE ENZYMES | INSTITUT PASTEUR (FR) | 2011-01-13 | — | — | WO | disclosed |
| EP-2272510-A1 | Inhibitors of the proline racemase of trypanosoma cruzi | Institut Pasteur (FR) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174649-A1 | CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE | CUL4A, CUL1, CUL3 | HCAR2 4254/4885RNASEH1 1780/4885SMN1; SMN2 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.